The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field.
Acromegaly; Growth hormone; Myopathy
Biagetti B, Simó R. GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice. Int J Mol Sci. 2021 Jan 2;22(1):415.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/7677
This item appears in following collections
The following license files are associated with this item: